Molecular subtyping of DLBCL shows promise in tailoring treatment
Two recent studies have looked at whether the particular molecular subtype of DLBCL can be used to tailor a person's treatment.
News
Research and clinical trials
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
No benefits from extra doses of rituximab in aggressive B-cell lymphoma
A recent clinical trial found that giving two additional doses of rituximab to people with aggressive B-cell lymphoma who responded to six cycles of R-CHOP did not improve outcomes.
Early results of phase 2 trial of polatuzumab vedotin for DLBCL
Adding polatuzumab vedotin to bendamustine and rituximab improves survival in patients with relapsed or refractory DLBCL.
New study confirms challenge of adjusting to life after lymphoma treatment
Study shows people want better preparation for transition from treatment to follow-up.
Promising results of oral chemotherapy drug for refractory low-grade NHL
Duvelisib reports promising efficacy in people with low-grade non-Hodgkin lymphomas who have not responded to previous treatment.
New report on the risk of second cancers in teenagers and young adults treated for cancer
Teenage and Young Adult Cancer Study published.
Institute of Cancer Research launch survey
Study seeks people newly diagnosed with diffuse large B-cell lymphoma
UK study researching impact of cancer on daily life across the UK.
Brentuximab vedotin plus chemo better than standard chemo for T-cell lymphoma
Results of the Echelon-2 study show that adding brentuximab vedotin to chemotherapy improves survival in people who have CD30-positive T-cell lymphomas
National study into late effects of Hodgkin lymphoma to double in size
The National Cohort Study researching late effects of Hodgkin lymphoma treatment will be the largest study of its kind in the world